Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

STOK stock hub

Stoke Therapeutics, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

STOKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

STOK

In the news

Latest news · STOK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-45.6

P25 -105.6P50 -46.5P75 -3.1

ROIC-300.6

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All STOK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

201

Groups with data

Currency

USD

Showing 201 of 201 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001623526
Company name	Stoke Therapeutics, Inc.
Country	United States
Country code	US
Cusip	86150R107
Employees	170
Employees Change	42%
Employees Change Percent	32.81
Enterprise value	$1.6B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2019-06-19
Isin	US86150R1077
Last refreshed	2026-05-10
Market cap	$2B
Market cap category	Mid-Cap
Price	$32.89
Price currency	USD
Rev Per Employee	188,705.88x
Sector	Healthcare
Sic	2834
Symbol	STOK
Website	https://www.stoketherapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.29%
EV Sales Forward	60.64x
EV/Sales	51.03x
FCF yield	-7.21%
P/B ratio	5.18x
P/S ratio	63.84x
PS Forward	75.87x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	100%
Gross Profit	$32.1M
Gross Profit Growth	-83.2%
Gross Profit Growth Q	-96.07%
Gross Profit Growth3 Y	30.13%
Net Income	$-169.8M
Net Income Growth Years	2%
Pretax Margin	-533.18%
Profit Per Employee	$-998,629
ROA	-27.24
Roa5y	-21.02
ROCE	-46.03
ROE	-45.58
Roe5y	-38.65
ROIC	-300.6

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	280.14%
Cagr3y	40.13%
Cagr5y	0.26%
EPS Growth Years	3
Revenue Growth	-83.2x
Revenue Growth Q	-96.07x
Revenue Growth Years	2x
Revenue Growth3 Y	30.13x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.08
Assets	$443.3M
Cash	$343.5M
Current Assets	$366.7M
Current Liabilities	$40.8M
Equity	$394.9M
Interest Coverage	-20,583.1
Liabilities	$48.4M
Long Term Assets	$76.6M
Long Term Liabilities	$7.6M
Net Cash	$411M
Net Cash By Market Cap	$20.07
Net Cash Growth	9.29%
Net Debt Equity	$-1.04
Tangible Book Value	$394.9M
Tangible Book Value Per Share	$6.34
WACC	10.86

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	8.99
Net Working Capital	$-17.7M
Quick ratio	8.57
Working Capital	$325.9M
Working Capital Turnover	$0.1

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-5.62%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	279.79%
200-day SMA	28.74
3Y total return	175.23%
50-day SMA	34.27
50-day SMA vs 200-day SMA	50over200
5Y total return	1.33%
All Time High	71.58
All Time High Change	-54.05%
All Time High Date	2021-01-20
All Time Low	3.35
All Time Low Change	881.79%
All Time Low Date	2023-10-27
ATR	1.74
Beta	1.2
Beta1y	0.93
Beta2y	1.58
Ch YTD	3.62
High	33.29
High52	40.22
High52 Date	2026-03-10
High52ch	-18.22%
Low	31.28
Low52	8.51
Low52 Date	2025-05-08
Low52ch	286.49%
Ma50ch	-4.03%
Price vs 200-day SMA	14.43%
RSI	44.61
RSI Monthly	69.03
RSI Weekly	54.46
Sharpe ratio	2.3x
Sortino ratio	4.21
Total Return	-5.62%
Tr YTD	3.62
Tr1m	-2.63%
Tr1w	-0.57%
Tr3m	1.51%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	10
Analyst Count Top	5
Analyst Price Target Top	$35
Analyst Ratings	Strong Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.81
Earnings Revenue Estimate	5,154,000x
Earnings Revenue Estimate Growth	-96.75x
Operating Income	$-185.2M
Operating margin	-577.5
Price target	$39.2
Price Target Change	$19.19
Price Target Change Top	$6.42

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	46,953,803%
Float Percent	75.4%
Shares Insiders	3.85%
Shares Institutions	95.24%
Shares Out	62,271,082
Shares Qo Q	1.65%
Shares Yo Y	5.62%
Short Float	26.7%
Short Ratio	14.97
Short Shares	20.13

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-181.9M
Average Volume	501,060.6x
Bv Per Share	6.34
CAPEX	$-871,000
Ch1m	-2.63
Ch1w	-0.57
Ch1y	279.8
Ch3m	1.51
Ch3y	175.2
Ch5y	1.33
Ch6m	43.88
Change	0.3%
Change From Open	3.04
Close	32.79
Days Gap	-2.65
Depreciation Amortization	1,732,000
Dollar Volume	22,796,947
Earnings Date	2026-05-07
Earnings Time	amc
EBIT	$-185.2M
EBITDA	$-183.5M
EPS	$-2.81
F Score	2
FCF	$-147.7M
FCF EV Yield	-9.02x
FCF Per Share	$-2.37
Financing CF	180,342,000
Fiscal Year End	December
Founded	2,014
Income Tax	$-1.3M
Investing CF	-149,750,000
Ipr	82.72
Iprfo	20.87
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-16
Ma150	31.99
Ma150ch	2.8%
Ma20	34.37
Ma20ch	-4.3%
Net CF	-116,232,000
Next Earnings Date	2026-05-22
Open	31.92
Optionable	Yes
Position In Range	80.1
Post Close	32.89
Postmarket Change Percent	0.33
Postmarket Price	$33
Ppne	5,888,000
Price Date	2026-05-08
Ptbv Ratio	5.19
Relative Volume	1.38x
Revenue	32,080,000x
SBC By Revenue	106.73x
Share Based Comp	34,238,000
Tax By Revenue	-3.98x
Tr6m	43.88%
Us State	Massachusetts
Volume	693,127

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does STOK pay a dividend?

Capital-return profile for this ticker.

Performance

STOK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns STOK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+95.2%

Float: +75.4% of shares outstanding

Insider ownership

+3.9%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

STOK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

44.6

Neutral momentum band

Price vs 200-day MA

+14.4%

50/200-day relationship not available

Beta (5Y)

1.20

More volatile than the market

Sharpe ratio

2.30

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About STOK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current STOK stock rating?

Stoke Therapeutics, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full STOK analysis?

The full report lives at /stocks/STOK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for STOK?

The latest report frames STOK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the STOK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.